SAN DIEGO, Sept. 16, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the 2015 Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York, NY on September 16, 2015.
William Welch, President and Chief Executive Officer, and Carolyn Beaver, Chief Financial Officer, will participate in a company "fireside chat" to be hosted by a Morgan Stanley analyst on Wednesday, September 16, beginning at 3:40pm, ET. The session is expected to last approximately 30 minutes and will be webcast live through the "Invest" section of the Sequenom Website at www.sequenom.com.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technologies, products, and diagnostic tests that target and serve molecular diagnostic markets. Web site: www.sequenom.com
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the development of innovative products and services. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SOURCE Sequenom, Inc.